ClinicalTrials.gg
CompletedNCT04065490Updated Oct 8, 2026Results posted

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

An interventional study of Valeda Light Delivery System and Valeda Light Delivery System Sham Mode in Dry Age-related Macular Degeneration, sponsored by LumiThera, Inc.. Completed at 10 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by LumiThera, Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Oct 8, 2026Now CompletedResults posted+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
176th of 491
100 · median 55
Started
2019
with 32 others
No phase
78 of 645
15 open now
Registered
430th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 176th largest by enrollment of the 491 interventional ones that give a count, is one of 33 that started in 2019, is one of 78 with no phase, and was the 430th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.

Alcon Research, LLC, acquired LumiThera in September 2025.

Read the detailed description

This study is a double-masked, sham-controlled, parallel design prospective, multi-site study on the use of photobiomodulation (PBM) as a treatment for visual impairment in subjects with dry AMD. Subjects will receive repeated sham or PBM treatments at several time-points throughout the 2-year study.

03

Conditions studied

  • Dry Age-related Macular Degeneration

Keywords

  • Dry age-related macular degeneration
  • Photobiomodulation
  • Visual Acuity
  • Contrast Sensitivity
  • Drusen
  • Optical coherence tomography
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female at least 50 years of age at Screening visit
  2. ETDRS BCVA letter score of between 50* and 75* (Snellen equivalent of 20/100 to 20/32). *If the subject meets this criterion at the Screening Visit, but the Baseline BCVA letter score is between 48 and 77, the subject may be entered in the study.
  3. Diagnosis of dry AMD as defined by the presence of the following:

    Drusen that are intermediate in size or larger (63 μm or larger in diameter) with at least a few (3) being regular drusen and not pseudodrusen and/or geographic atrophy (GA) visible on two of the following: color fundus images, OCT and/or FAF, to be confirmed by the reading center

  4. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study
  5. Informed of the nature of this study and has provided written, in accordance with institutional, local and national regulatory guidelines

Exclusion criteria

Exclusion Criteria:

  1. Current or history of neovascular maculopathy that includes any of the following (to be confirmed by the reading center):

    1. Choroidal neovascularization (CNV) defined as pathologic angiogenesis originating from the choroidal vasculature that extends through a defect in Bruch's membrane
    2. Serous and/or hemorrhagic detachment of the neurosensory retina or retinal pigment epithelial (RPE)
    3. Retinal hard exudates (a secondary phenomenon resulting from chronic intravascular leakage)
    4. Subretinal and sub-RPE fibrovascular proliferation
    5. Disciform scar (subretinal fibrosis)
  2. Presence of center involving GA within the central ETDRS 1 mm diameter at Screening, to be confirmed by the reading center
  3. Media opacities, including cataracts, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require cataract surgery in the study eye in the next 24 months.
  4. Posterior capsule opacification, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require surgery in the study eye in the next 24 months.
  5. Invasive eye surgery (e.g. cataract, capsulotomy) on a qualifying eye within three 3 months prior to Screening
  6. Ocular disorder or disease that partially or completely obstructs the pupil (e.g. posterior synechia in uveitis)
  7. Visually significant disease in any ocular structure apart from dry AMD (e.g. diabetic macular edema, glaucoma (using >2 eye drop medications, uncontrolled IOP and/or central/paracentral visual field loss), glaucoma surgery, active uveitis, active vitreous disease, intraocular tumor, retinal vascular diseases)
  8. Ocular disorder or disease other than dry AMD that could cause drusen (glomerulonephritis Type 2, Autosomal dominant drusen), GA (North Carolina dystrophy) or mitochondrial diseases (parafoveal petaloid GA, Stargardt disease)
  9. Presence or history of disease or condition affecting functional vision without obvious structural abnormalities (e.g. amblyopia, stroke, nystagmus)
  10. Serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study
  11. Presence of or history of within the past 5 years other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ
  12. Is non-ambulatory
  13. Presence or history of known light sensitivity to yellow light, red light, or near infrared radiation (NIR), or if they have a history of light activated CNS disorders (e.g. epilepsy, migraine)
  14. Use of any photosensitizing agent (e.g. topicals, injectables, oral) within 30 days of treatment without consulting subject's physician
  15. History of drug, alcohol or substance abuse within 3 months prior to Screening
  16. Has received an drug or treatment with an investigational device within 3 months prior to Screening
  17. If on any anti-oxidant or vitamin Age-Related Eye Disease Study (AREDS) supplement for dry AMD, has not been stabilized for a minimum of 1 month prior to Screening. Subjects are considered to be stable if they are taking the AREDS supplements consistently as prescribed by their treating doctor.
  18. Has received Low Vision Rehab/Therapy within 30 days prior to Screening or intends to receive during the study
  19. Has an open sore(s) that may come in contact with the Valeda System, has periorbital skin erythema or is prone to such conditions with exposure to light.
  20. In the opinion of the Investigator, is unlikely to comply with the study protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    PBM Treatment

    Valeda Light Delivery System: 3 PBM treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4, 8, 12, 16 and 20.

    Device: Valeda Light Delivery System

  • Sham comparator
    Sham Treatment

    Valeda Light Delivery System Sham Mode: 3 sham treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4, 8, 12, 16 and 20.

    Device: Valeda Light Delivery System Sham Mode

Interventions

  • DeviceValeda Light Delivery System

    Light delivery system that produces multi-wavelength LED treatment at 590, 660 and 850 nanometers.

  • DeviceValeda Light Delivery System Sham Mode

    Sham light delivery system that emits an approximate 50 times and 100 times reduction in treatment dose for the 590 and 660 nm wavelengths respectively and no emission of the 850 nm wavelength.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21

    Best Corrected Visual Acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. Each line on the chart had exactly five letters, uniform spacing, and a proportional decrease in letter size, providing an equal level of difficulty for every single line read by the patient. A positive change in number of letters read indicates an improvement in visual acuity.

    Time frame: Baseline (Day 0, pretreatment), Month 21

Secondary outcomes

  1. Mean Change From Baseline in Contrast Sensitivity (40 Centimeters) at Month 21

    The Mars Contrast Sensitivity Test (Mars CS Test) is a vision test that measures how well a person can see objects that do not stand out clearly from their background. The test consisted of a set of charts that scored visual function from 0 (profound loss) to 1.92 (normal) vision at a distance of 40 centimeters. A positive change value indicates an improvement.

    Time frame: Baseline (Day 0, pretreatment), Month 21

  2. Mean Change From Baseline in Central Drusen Volume at Month 21

    Drusen are yellowish deposits of lipids, cholesterol, and cellular waste products that accumulate underneath the retinal pigment epithelium (RPE). They are one of the hallmark signs of age-related macular degeneration (AMD). Central drusen volume is a measurement of the total amount of drusen material in the center of the retina (the macula). Central drusen volume was measured by optical coherence tomography and fundus autofluorescence imaging. A smaller change represents lesser damage to the retina.

    Time frame: Baseline (Day 0, pretreatment), Month 21

  3. Mean Change From Baseline in Low Luminance Best Corrected Visual Acuity (LLBCVA) at Month 21

    Low Luminance Best Corrected Visual Acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. A 2.0 log unit neutral density filter was added to create the low lighting conditions. Each line on the chart had exactly five letters, uniform spacing, and a proportional decrease in letter size, providing an equal level of difficulty for every single line read by the patient. A positive change in number of letters read indicates an improvement in visual acuity.

    Time frame: Baseline (Day 0, pretreatment), Month 21

Other outcomes

  1. Mean Change From Baseline in VFQ-25 Composite Score at Month 21

    VFQ-25 (National Eye Institute Visual Function Questionnaire-25, NEI VFQ-25) is a patient-reported outcome instrument designed to measure the impact of visual impairment on quality of life and daily functioning across 12 domains. Responses are recoded according to the official NEI scoring manual to a 0-100 scale, where 100 = best possible visual function/no impairment and 0 = worst possible visual function/maximum impairment. Intermediate response categories are transformed proportionally. The composite score is the sum of the 12 domains divided by 11. A composite score of 90-100 is considered minimal vision-related impairment; 70-89 is considered mild impairment; 50-69 is considered moderate impairment; and less than 50 is considered significant vision-related functional impairment. Positive change represents an improvement. This was a subject-based assessment and subject assigned a single score for both eyes.

    Time frame: Baseline (Day 0, pretreatment), Month 21

  2. Mean Change From Baseline in Radner Reading Speed at Month 21

    Reading speed was assessed using the Radner Reading Chart, a standardized eye test that is used to measure a person's functional reading ability. The subject read short sentences in progressively smaller print while the examiner measured reading speed and accuracy. Reading speed (words per minute) was calculated as \[Number of correctly read words x 60\] / Reading time (seconds). A positive change in reading speed represents an improvement.

    Time frame: Baseline (Day 0, pretreatment), Month 21

  3. Mean Change From Baseline in Geographic Atrophy Lesion Area at Month 21

    A geographic atrophy lesion (GA) is the specific area in the retina where the retina has thinned or disappeared due to GA, exposing deeper structures of the eye. GA lesion area was measured using fundus autofluorescence (FAF), a noninvasive eye imaging test that uses a camera to photograph the back of the eye and highlight damaged retinal cells. A smaller change in area from baseline represents slower legion growth (lesser damage to the retina).

    Time frame: Baseline (Day 0, pretreatment), Month 21

07

Results

Posted Oct 8, 2026

Participant flow

Subjects were recruited and enrolled at 10 investigative sites located in the United States.

Participant flow — Overall Study
MilestonePBM TreatmentSham Treatment
Started6535
Month 21 (mitt population)6434
Completed5327
Not completed128
Withdrew: Withdrawal of consent84
Withdrew: Unable to return to facility22
Withdrew: Adverse event22

Outcome measures

PrimaryMean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21

Best Corrected Visual Acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. Each line on the chart had exactly five letters, uniform spacing, and a proportional decrease in letter size, providing an equal level of difficulty for every single line read by the patient. A positive change in number of letters read indicates an improvement in visual acuity.

Time frame:
Baseline (Day 0, pretreatment), Month 21
Reported as:
Mean · letters
Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21
lettersPBM TreatmentSham Treatment
Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 216.2 ± 1.022.4 ± 1.26
Statistical analysis
  • PBM Treatment vs Sham Treatment · Multiple imputation · p = 0.0036
SecondaryMean Change From Baseline in Contrast Sensitivity (40 Centimeters) at Month 21

The Mars Contrast Sensitivity Test (Mars CS Test) is a vision test that measures how well a person can see objects that do not stand out clearly from their background. The test consisted of a set of charts that scored visual function from 0 (profound loss) to 1.92 (normal) vision at a distance of 40 centimeters. A positive change value indicates an improvement.

Time frame:
Baseline (Day 0, pretreatment), Month 21
Reported as:
Mean · score on a scale
Mean Change From Baseline in Contrast Sensitivity (40 Centimeters) at Month 21
score on a scalePBM TreatmentSham Treatment
Mean Change From Baseline in Contrast Sensitivity (40 Centimeters) at Month 210.03 ± 0.080.07 ± 0.07
Statistical analysis
  • PBM Treatment vs Sham Treatment · Multiple imputation · p = 0.82
SecondaryMean Change From Baseline in Central Drusen Volume at Month 21

Drusen are yellowish deposits of lipids, cholesterol, and cellular waste products that accumulate underneath the retinal pigment epithelium (RPE). They are one of the hallmark signs of age-related macular degeneration (AMD). Central drusen volume is a measurement of the total amount of drusen material in the center of the retina (the macula). Central drusen volume was measured by optical coherence tomography and fundus autofluorescence imaging. A smaller change represents lesser damage to the retina.

Time frame:
Baseline (Day 0, pretreatment), Month 21
Reported as:
Mean · mm3
Mean Change From Baseline in Central Drusen Volume at Month 21
mm3PBM TreatmentSham Treatment
Mean Change From Baseline in Central Drusen Volume at Month 210.056 ± 0.010.098 ± 0.1
Statistical analysis
  • PBM Treatment vs Sham Treatment · Multiple imputation · p = 0.65
SecondaryMean Change From Baseline in Low Luminance Best Corrected Visual Acuity (LLBCVA) at Month 21

Low Luminance Best Corrected Visual Acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. A 2.0 log unit neutral density filter was added to create the low lighting conditions. Each line on the chart had exactly five letters, uniform spacing, and a proportional decrease in letter size, providing an equal level of difficulty for every single line read by the patient. A positive change in number of letters read indicates an improvement in visual acuity.

Time frame:
Baseline (Day 0, pretreatment), Month 21
Reported as:
Mean · letters
Mean Change From Baseline in Low Luminance Best Corrected Visual Acuity (LLBCVA) at Month 21
lettersPBM TreatmentSham Treatment
Mean Change From Baseline in Low Luminance Best Corrected Visual Acuity (LLBCVA) at Month 213.1 ± 1.344.9 ± 1.58
Statistical analysis
  • PBM Treatment vs Sham Treatment · Multiple imputation · p = 0.29
Other pre-specifiedMean Change From Baseline in VFQ-25 Composite Score at Month 21

VFQ-25 (National Eye Institute Visual Function Questionnaire-25, NEI VFQ-25) is a patient-reported outcome instrument designed to measure the impact of visual impairment on quality of life and daily functioning across 12 domains. Responses are recoded according to the official NEI scoring manual to a 0-100 scale, where 100 = best possible visual function/no impairment and 0 = worst possible visual function/maximum impairment. Intermediate response categories are transformed proportionally. The composite score is the sum of the 12 domains divided by 11. A composite score of 90-100 is considered minimal vision-related impairment; 70-89 is considered mild impairment; 50-69 is considered moderate impairment; and less than 50 is considered significant vision-related functional impairment. Positive change represents an improvement. This was a subject-based assessment and subject assigned a single score for both eyes.

Time frame:
Baseline (Day 0, pretreatment), Month 21
Reported as:
Mean · score on a scale
Mean Change From Baseline in VFQ-25 Composite Score at Month 21
score on a scalePBM TreatmentSham Treatment
Mean Change From Baseline in VFQ-25 Composite Score at Month 211.5 ± 1.63-3.7 ± 2.02
Statistical analysis
  • PBM Treatment vs Sham Treatment · Multiple imputation · p = 0.0182
Other pre-specifiedMean Change From Baseline in Radner Reading Speed at Month 21

Reading speed was assessed using the Radner Reading Chart, a standardized eye test that is used to measure a person's functional reading ability. The subject read short sentences in progressively smaller print while the examiner measured reading speed and accuracy. Reading speed (words per minute) was calculated as \[Number of correctly read words x 60\] / Reading time (seconds). A positive change in reading speed represents an improvement.

Time frame:
Baseline (Day 0, pretreatment), Month 21
Reported as:
Mean · words per minute
Mean Change From Baseline in Radner Reading Speed at Month 21
words per minutePBM TreatmentSham Treatment
Mean Change From Baseline in Radner Reading Speed at Month 21-1.4 ± 9.50.6 ± 11.17
Statistical analysis
  • PBM Treatment vs Sham Treatment · Multiple imputation · p = 0.12
Other pre-specifiedMean Change From Baseline in Geographic Atrophy Lesion Area at Month 21

A geographic atrophy lesion (GA) is the specific area in the retina where the retina has thinned or disappeared due to GA, exposing deeper structures of the eye. GA lesion area was measured using fundus autofluorescence (FAF), a noninvasive eye imaging test that uses a camera to photograph the back of the eye and highlight damaged retinal cells. A smaller change in area from baseline represents slower legion growth (lesser damage to the retina).

Time frame:
Baseline (Day 0, pretreatment), Month 21
Reported as:
Mean · mm2
Mean Change From Baseline in Geographic Atrophy Lesion Area at Month 21
mm2PBM TreatmentSham Treatment
Mean Change From Baseline in Geographic Atrophy Lesion Area at Month 212.06 ± 0.642.53 ± 0.91
Statistical analysis
  • PBM Treatment vs Sham Treatment · Multiple imputation · p = 0.52

Adverse events

Collected over Adverse events were collected from time of consent until study exit, approximately 24 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PBM Treatment0/65 (0%)7/93 (7.5%)1/93 (1.1%)
Sham Treatment0/35 (0%)3/55 (5.5%)4/55 (7.3%)
Most frequent serious events
Most frequent serious events
EventPBM TreatmentSham Treatment
Neovascular age-related macular degenerationEye disorders7/932/55
Cystoid Macular EdemaEye disorders0/931/55
Most frequent other events
Most frequent other events
EventPBM TreatmentSham Treatment
Vitreous FloatersEye disorders1/934/55

Baseline characteristics

Safety Analysis Set: All qualifying eyes of subjects that signed the Informed Consent Form, were randomized, and received at least one study treatment.

Age, Customized
Age, Customized(years)PBM TreatmentSham TreatmentTotal
Mean74.4 ± 7.377.1 ± 6.275.4 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)PBM TreatmentSham TreatmentTotal
Female462268
Male191332
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PBM TreatmentSham TreatmentTotal
Hispanic or Latino336
Not Hispanic or Latino623294
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PBM TreatmentSham TreatmentTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White653499
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)PBM TreatmentSham TreatmentTotal
United States6535100
08

Study locations

10 sites
  • Retina Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • Stanford University
    Palo Alto, California 94303, United States
  • Florida Eye Clinic
    Altamonte Springs, Florida 32701, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21749, United States
  • Mid Atlantic Retina
    Cherry Hill, New Jersey 19107, United States
  • New York Ear and Eye Infirmary
    New York, New York 10003-4284, United States
  • Duke Eye Center
    Durham, North Carolina 27705, United States
  • Cumberland Valley Retina Consultants
    Chambersburg, Pennsylvania 17201, United States
  • Gulf Coast Eye Institute
    McAllen, Texas 78503, United States
  • Retina Center Northwest
    Silverdale, Washington 98383, United States
09

References and documents

Publications

  • Jaffe GJ, Boyer D, Hu A, Warrow D, Xavier S, Gonzalez V, Lad E, Rosen RB, Do DV, Schneiderman T, Ho AC, Munk MR, Tedford SE, Croissant CL, Ruckert R, Lavin PT, Tedford CE. LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS). Retina. 2026 May 1;46(5):783-795. doi: 10.1097/IAE.0000000000004822. PubMed 41791029 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jan 2023, 40 months.

Results were first posted in Oct 2026, 3 years 8 months after primary completion.

Of 133 interventional studies with no phase under Macular Degeneration, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's 40 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Jun 2022 → Jan 2023 and completion Jun 2022 → Nov 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2019
First posted
Aug 22, 2019
StartActual
Sep 23, 2019
Primary completionActual
Jan 24, 2023was Jun 2022
CompletionActual
Nov 1, 2024was Jun 2022
Results first posted
Oct 8, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 8, 2026
Results
Results posted
posted Oct 8, 2026
Sites
1 site removed
Show 1 removed
  • Retina Consultants of Houston · The Woodlands, United States
Oct 8, 2026
Start date
Sep 1, 2019→Sep 23, 2019
Oct 8, 2026
Primary completion
Jun 1, 2022→Jan 24, 2023 (actual)
Oct 8, 2026
Study completion
Jun 1, 2022→Nov 1, 2024 (actual)
Oct 8, 2026
Enrollment
96 (estimated)→100 (actual)
Oct 8, 2026
Interventions
Added Device: Valeda Light Delivery System·Device: Valeda Light Delivery System Sham Mode; removed Device: Valeda PBM treatment·Device: Valeda Sham treatment
Oct 8, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Best Corrected Visual AcuityNow Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21Time frame: 21 months → Baseline (Day 0, pretreatment), Month 21
Oct 8, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41791029 ↗
Oct 8, 2026
Secondary outcomes
6 added, 8 removed
What changed in the outcomes
  • AddedMean Change From Baseline in Contrast Sensitivity (40 Centimeters) at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
  • AddedMean Change From Baseline in Central Drusen Volume at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
  • AddedMean Change From Baseline in Low Luminance Best Corrected Visual Acuity (LLBCVA) at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
  • RemovedContrast SensitivityTime frame: 21 months
  • RemovedCentral Drusen VolumeTime frame: 21 Months
  • RemovedCentral Drusen ThicknessTime frame: 21 Months
  • Addedother outcomeMean Change From Baseline in VFQ-25 Composite Score at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
  • Addedother outcomeMean Change From Baseline in Radner Reading Speed at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
  • Addedother outcomeMean Change From Baseline in Geographic Atrophy Lesion Area at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
  • Removedother outcomeContrast SensitivityTime frame: 21 Months
  • Removedother outcomeVisual Function QuestionnaireTime frame: 21 Months
  • Removedother outcomeReading SpeedTime frame: 21 Months
  • Removedother outcomeGeographic AtrophyTime frame: 21 Months
  • Removedother outcomeLow Luminance- Best Corrected Visual AcuityTime frame: 21 Months
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Active, not recruiting→Completed
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41791029 ↗
    1 site removed
    Show 1 removed
    • Retina Consultants of Houston · The Woodlands, United States
    Start date Sep 1, 2019→Sep 23, 2019
    Primary completion Jun 1, 2022→Jan 24, 2023 (now actual)
    Study completion Jun 1, 2022→Nov 1, 2024 (now actual)
    Enrollment 96 (estimated)→100 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Best Corrected Visual AcuityNow Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21Time frame: 21 months → Baseline (Day 0, pretreatment), Month 21
    Secondary outcomes 6 added, 8 removed
    What changed in the outcomes
    • AddedMean Change From Baseline in Contrast Sensitivity (40 Centimeters) at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
    • AddedMean Change From Baseline in Central Drusen Volume at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
    • AddedMean Change From Baseline in Low Luminance Best Corrected Visual Acuity (LLBCVA) at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
    • RemovedContrast SensitivityTime frame: 21 months
    • RemovedCentral Drusen VolumeTime frame: 21 Months
    • RemovedCentral Drusen ThicknessTime frame: 21 Months
    • Addedother outcomeMean Change From Baseline in VFQ-25 Composite Score at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
    • Addedother outcomeMean Change From Baseline in Radner Reading Speed at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
    • Addedother outcomeMean Change From Baseline in Geographic Atrophy Lesion Area at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21
    • Removedother outcomeContrast SensitivityTime frame: 21 Months
    • Removedother outcomeVisual Function QuestionnaireTime frame: 21 Months
    • Removedother outcomeReading SpeedTime frame: 21 Months
    • Removedother outcomeGeographic AtrophyTime frame: 21 Months
    • Removedother outcomeLow Luminance- Best Corrected Visual AcuityTime frame: 21 Months
    Interventions Added Device: Valeda Light Delivery System·Device: Valeda Light Delivery System Sham Mode; removed Device: Valeda PBM treatment·Device: Valeda Sham treatment
    + 6 other changes: index terms, verification date, oversight details, description, design details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04065490
Lead sponsor
LumiThera, Inc.
Responsible party
Sponsor
First posted
Aug 22, 2019
Start date
Sep 23, 2019
Primary completion
Jan 24, 2023
Completion
Nov 1, 2024
Results posted
Oct 8, 2026
Last update
Oct 8, 2026

Study contacts

Director, Clinical Trial Management, Surgical
study director · Alcon Research, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion